Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Yi M, Li T, Niu M, et al. Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomark Res. 2021;9:55.

Article  PubMed  PubMed Central  Google Scholar 

Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136–45.

Article  CAS  PubMed  Google Scholar 

Poteat TC, Adams MA, Malone J, et al. Delays in breast cancer care by race and sexual orientation: results from a national survey with diverse women in the United States. Cancer. 2021;127:3514–22.

Article  PubMed  Google Scholar 

Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

Article  CAS  PubMed  Google Scholar 

Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed african-american and caucasian patients: a single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer. 2007;110:876–84.

Article  PubMed  Google Scholar 

Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.

Article  PubMed  Google Scholar 

Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.

Article  CAS  PubMed  Google Scholar 

Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: Where are we? Int J Cancer. 2012;131:2471–7.

Article  CAS  PubMed  Google Scholar 

Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15:143.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.

Article  PubMed  Google Scholar 

Kumar H, Gupta NV, Jain R, et al. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res; 2023.

Yi M, Zhang D, Song B, et al. Increased expression of ECT2 predicts the poor prognosis of breast cancer patients. Exp Hematol Oncol. 2022;11:107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spínola-Lasso E, Montero JC, Jiménez-Monzón R, et al. Chemical-proteomics identify Peroxiredoxin-1 as an actionable target in triple-negative breast cancer. Int J Biol Sci. 2023;19:1731–47.

Article  PubMed  PubMed Central  Google Scholar 

Dong B, Yi M, Luo S, Li A, Wu K. RDGN-based predictive model for the prognosis of breast cancer. Exp Hematol Oncol. 2020;9:13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo L, Kong D, Liu J, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12:3.

Article  PubMed  PubMed Central  Google Scholar 

Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(428–40): e5.

Google Scholar 

Xiao Y, Ma D, Yang YS, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022;32:477–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Jiang Z. Chinese society of clinical oncology breast cancer (CSCO BC) guidelines in 2022: Stratification and classification. Cancer Biol Med. 2022;19:769–73.

Article  PubMed  PubMed Central  Google Scholar 

Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380–8.

Article  CAS  PubMed  Google Scholar 

Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu YR, Jiang YZ, Xu XE, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016;18:33.

Article  PubMed  PubMed Central  Google Scholar 

Zhao S, Ma D, Xiao Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist. 2020;25:e1481–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the future trial. Cell Res. 2021;31:178–86.

Article  CAS  PubMed  Google Scholar 

Li T, Wang X, Qin S, et al. Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies. Biomed Pharmacother. 2023;162:114712.

Article  CAS  PubMed  Google Scholar 

Yi M, Dong B, Qin S, et al. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol. 2019;8:29.

Article  PubMed  PubMed Central  Google Scholar 

Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: The most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022;31:607–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32:240–9.

Article  CAS  PubMed  Google Scholar 

Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.

Article  CAS  PubMed  Google Scholar 

Robson ME, Tung N, Conte P, et al. Olympiad final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for patients with brca1- or brca2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.

Article  CAS  PubMed  Google Scholar 

Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant Talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38:388–94.

Article  CAS  PubMed  Google Scholar 

Beniey M, Hubert A, Haque T, et al. Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. Br J Cancer. 2023;128:1964–75.

Article  CAS  PubMed  PubMed Central  Google Scholar